Substituted amines for treating cardiac diseases

US11197858B2 · kind B2 · utility

Assignee

• Cardurion Pharmaceuticals, Inc. · US

Inventors

• Nobuyuki Matsunaga · Yokohama, JP
• Takashi Nakahata · Fujisawa, JP
• Yuta Tanaka · Fujisawa, JP
• Hiroki Takahagi · Yokohama, JP
• Yasufumi Miyamoto · Osaka, JP
• Rei Okamoto · Yokohama, JP
• Takeshi Yoshikawa · Yokohama, JP
• Yoshito Terao · Osaka, JP
• Takafumi YUKAWA · Yokohama, JP
• Keiko Kakegawa · Yokohama, JP
• Yoichi Nishikawa · Yokohama, JP
• Terufumi Takagi · Osaka, JP
• Masashi Takahashi · Yokohama, JP
• Mallareddy Komandla · San Diego, US
• Lily Kwok · San Diego, US
• Joanne Miura · San Diego, US
• Mark Sabat · Loveland, US
• Nicholas Scorah · San Diego, US
• Paul TANIS · San Diego, US
• John Tyhonas · San Diego, US
• Phong Vu · San Diego, US
• Haixia Wang · San Diego, US
• Xiaolun Wang · San Diego, US
• Junya Shirai · Osaka, JP
• Tomohiro Okawa · Yokohama, JP
• Zenyu Shiokawa · Yokohama, JP
• Akito Shibuya · Yokohama, JP

Key dates

• Filing date: Jan 27, 2020
• Grant date: Dec 14, 2021
• Expiry date: Jan 27, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P9/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.